Get started
Author

Paul Baverel

Observed names: P. Baverel, Paul G. Baverel, Paul Gabriel Baverel
Observed institutions: AstraZeneca (United Kingdom), F. Hoffmann-La Roche AG, Uppsala University, Pfizer (United Kingdom), University of Cambridge, Molecular Partners (Switzerland), Roche Pharma (Schweiz) AG (Switzerland)
ORCID: 0000-0002-2461-5849
Observed ORCID: 0000-0002-2461-5849
OpenAlex ID: A5025497378
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
2017 · Paul G. Baverel, Vincent F.S. Dubois, et al. · Clinical Pharmacology & Therapeutics · 156
PDF
Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point
2013 · Emma C.Y. Hilton, Paul G. Baverel, et al. · Journal of Allergy and Clinical Immunology · 91
PDF
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development
2023 · Ana Ruiz-Garcia, Paul Baverel, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 60
PDF
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
2017 · Yanan Zheng, Rajesh Narwal, et al. · Clinical Pharmacology & Therapeutics · 58
PDF
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
2019 · Padmanee Sharma, Joohyuk Sohn, et al. · Clinical Cancer Research · 45
Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol
2022 · Benjamin Ribba, Dominic Stefan Bräm, et al. · CPT Pharmacometrics & Systems Pharmacology · 30
PDF
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing
2015 · Paul G. Baverel, Meena Jain, et al. · British Journal of Clinical Pharmacology · 30
PDF
Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
2019 · Paul Baverel, Lorin Roskos, et al. · Clinical and Translational Science · 23
PDF
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers
2017 · Paul Baverel, Dewei She, et al. · Drug Metabolism and Pharmacokinetics · 19
PDF
Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial
2022 · Sandrine Micallef, Alexandre Sostelly, et al. · Contemporary Clinical Trials Communications · 16
PDF
Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma
2021 · Rosalinda Arends, Xiang Guo, et al. · OncoImmunology · 15
Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy
2021 · Ignacio González‐García, Vadryn Pierre, et al. · CPT Pharmacometrics & Systems Pharmacology · 14
PDF
Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models
2021 · Van Thuy Truong, Paul G. Baverel, et al. · CPT Pharmacometrics & Systems Pharmacology · 13
PDF
Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models
2010 · Paul G. Baverel, Radojka M. Savic, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 13
Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors.
2017 · Paul Baverel, Vincent Dubois, et al. · Journal of Clinical Oncology · 11
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
2026 · Neeltje Steeghs, Carlos Gomez-Roca, et al. · Nature Cancer · 10
PDF
MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
2024 · Mojca Jongen-Lavrencic, Thomas Pabst, et al. · Blood · 10
PDF
Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma
2017 · Paul G. Baverel, Nicholas White, et al. · Clinical Pharmacology & Therapeutics · 10
Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.
2017 · Thomas Powles, Chaoyu Jin, et al. · Journal of Clinical Oncology · 9
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
2024 · Neeltje Steeghs, Carlos A. Gomez-Roca, et al. · Journal of Clinical Oncology · 8
Evaluation of the nonparametric estimation method in nonmem VI: application to real data
2009 · Paul G. Baverel, Radojka M. Savic, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 8
MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study
2023 · Thomas Pabst, Mojca Jongen-Lavrencic, et al. · Blood · 5
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
2023 · Carlos A. Gomez-Roca, Neeltje Steeghs, et al. · Journal of Clinical Oncology · 5
Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total
2021 · John Hood, Ignacio González-García, et al. · Pharmaceutics · 5
PDF
Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.
2020 · Vadryn Pierre, Xiang Guo, et al. · Journal of Clinical Oncology · 3
Works count: 40
Citation count: 671
H-index: 13
I10-index: 18
Year
Topic
Type